An observational study in Psychiatric Disorders, Cognitive Impairment and Chronic Hepatitis c, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Azienda Ospedaliero Universitaria di Cagliari · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 43rd largest by enrollment of the 64 observational ones that give a count, is one of 4 that started in 2015, is one of 64 observational ones, and was the 17th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 18–85 · Healthy volunteers
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
Alfonso Magliacano · Sites in Italy
Ages 18–75 · Healthy volunteers
University of Milano Bicocca · Sites in Italy
Ages 65+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 8 · Phase 4 1
First in 2007; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 80 across the 111 interventional studies, 182 across the 64 observational. Of the 59 that completed or were terminated, 7 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 175 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero Universitaria di Cagliari is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Azienda Ospedaliero Universitaria di Cagliari has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
23 of the studies in Cognitive Dysfunction with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06657274IRCCS Centro San Giovanni di Dio FatebenefratelliEARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069 | 2026-11-30 |
| NCT07286448Giovanna ZamboniPersonalized Digital Training for COGnitive FITness in Mild Cognitive Impairment | 2026-11-30 |
| NCT06701630Casa di Cura IGEAItalian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia. | 2026-11-30 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 175 studies in Cognitive Dysfunction with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic hepatitis HCV-related is the most common cause of chronic liver disease in Italy. Patients with chronic hepatitis C present a prevalence of depressive disorders higher than that of the general population; moreover, it has been repeatedly demonstrated the presence of cognitive deficits and poor quality of life. Chronic hepatitis C therapy was based on the combined use of pegylated alpha-interferons (PEG-INF), and ribavirin. Recently, new therapeutic protocols have been introduced, and while some antiviral drugs, including the first-generation ones, were used only in combination with PEG-IFN and ribavirin, the second and third generation antiviral drugs protocols are interferon-free. However, because of the high cost, the access to interferon-free protocols is only for patients with advanced fibrous stages, or with concomitant extra-hepatic HCV-related diseases, or for transplanted patients. Many side effects, such as flu-like symptoms, and psychiatric symptoms (depression, anxiety, irritability, insomnia) are common during antiviral therapy with IFN. However, in patients with chronic hepatitis C, a high lifetime prevalence of major depressive disorder, panic disorder, and brief recurrent depression have been observed, irrespective of IFN treatment and the use of alcohol and narcotics; such associations between mood and anxiety disorders and chronic hepatitis C may reflect a high prevalence of bipolar spectrum disorders. The presence of severe psychopathological symptoms requires the reduction of posology and causes high rates of discontinuation of antiviral therapy.
This project represents an innovative psychiatric and neuropsychological screening program for patients with chronic hepatitis C, eligible for antiviral therapy.
Primary objectives:
Main secondary objectives:
Background HCV-related chronic hepatitis represents the most common cause of chronic liver disease in Italy, with an estimated prevalence of 1-1.1% in the general population, reaching about 15% in subjects over 50 years of age. Chronic HCV infection is the cause of 27% of cases of cirrhosis and 25% of cases of hepatocarcinoma. Persons with chronic hepatitis C present a prevalence of depressive disorders higher than that of the general population (59% vs. 21%). Moreover, there has been repeatedly demonstrated the presence of cognitive deficits, mainly concerning attentive, executive, and verbal comprehension, also in the absence of liver cirrhosis and comorbidities due to the use of substances, and a reduced quality of life. Chronic hepatitis C therapy was based on the combined use of pegylated alpha interferons (PEG-INF) and ribavirin, with SVR (sustained virological response, defined as HCV-RNA undetectable in serum at six months after the end of therapy), normalization of transaminases and improvement of liver histology, altogether in 60% of cases. Recently, new antiviral drugs with direct activity (e.g. antiprotease and antipolymer activity) have been introduced into hepatitis C therapeutic protocols, with the development of PEG-INF-free therapeutic schemes. Unfortunately, because of the excessive cost, in many Countries, including Italy, the access to PEG-INF-free schemas is only for patients with advanced fibrous stages, or who have concomitant extra-hepatic viral diseases HCV-related, or those already transplanted, while others are still expected to be treated with PEG-INF and ribavirin.
There are frequent side effects of antiviral therapy, often of minor magnitude, but sometimes incompatible with the continuation of therapy or life threatening. The most common adverse effects are influenza-like symptoms, occurring in more than half of the patients, especially during the first treatment period, and psychiatric symptoms (depression, anxiety, irritability, insomnia), which occur around the third month of treatment from 12 to 41% of patients. However, in persons with chronic hepatitis C, a high lifetime prevalence of major depressive disorder and panic disorder, and brief recurrent depression have been observed, irrespective of PEG-INF treatment and the use of alcohol and narcotic drugs; such associations between mood and anxiety disorders and chronic hepatitis C may reflect a high prevalence of bipolar disorder, which is more difficult to diagnose using non-dedicated screening tools. Some symptoms before treatment start, such as lack of pleasure or interest, asthenia, loss of appetite, social withdrawal, reduced work function, and hostility, are highly predictive of the onset of depressive disorders during antiviral therapy. Poor cognitive performance prior to antiviral therapy, coupled with the only depressive symptom of sadness, is predictive of more severe depressive disorders during antiviral treatment. However, cognitive deficits found before therapy appear potentially reversible and tend to completely recede when there is a virological response sustained by antiviral therapy. The presence of severe psychopathological symptoms leads to a reduction in posology and high rates of discontinuation of antiviral therapy.
Careful psychiatric and neuropsychological evaluation before, during and after antiviral treatment should therefore be an indispensable part of screening and HCV-related chronic hepatitis therapy. This project represents an innovative psychiatric and neuropsychological screening program for persons with chronic hepatitis C, eligible for antiviral therapy. This program aims:
Early identification of subjects at risk of psychiatric and cognitive disorders during antiviral therapy will effectively treat individuals at risk of discontinuing the antiviral therapy itself, improving the quality of the treatment and the effectiveness of the treatments.
Design Observational study on a sample of persons with chronic hepatitis C. The experimental cohort will consist of participants who will be admitted to new antiviral treatments. The control cohort will consist of subjects recruited later, for which there is no immediate possibility of access to new treatments (wait-list).
Selection of the sample
The study will be conducted at the Center for the Study of Liver Diseases at the University Hospital of Monserrato, Cagliari. It is intended for subjects with chronic hepatitis C consecutively afferent to the facility, eligible for antiviral therapy. From the whole sample of cases will be drawn two cohorts:
Statistical analysis The data analysis will be carried out after the end of the study and in the next 3 months, by setting up a complete database for each participant, including in an anonymous form the socio-demographic and anamnestic data, and the data from the assessments performed at baseline and in subsequent times. The sample will be analyzed for frequency of lifetime and current psychiatric disorders, current cognitive deficits, subjectively perceived Quality of Life, depressive, hypomanic and manic symptoms, and patterns of biological rhythms. Data analysis will be done with multivariate techniques, for evaluating the effect and interaction of the various factors. The presence of psychiatric disorders and cognitive deficits will be considered dependent variables. The psychopathological specificity of symptoms related to antiviral treatment will also be measured in terms of different frequencies of specific psychiatric/neuropsychological symptoms and specific profiles of response to antiviral therapy. The whole sample will be compared at the baseline with a normative sample extracted with a computerized matching technique (4 controls each case) by gender and age from the database of a Italian population study. Through matchings 1: 4 it will be possible to increase the sample size and increase the statistical power of the study. The data analyses will be performed through SPSS (Statistical Package for Social Science) software.
Funding This project is a spontaneous study, without any source of funding. Ethical Aspects The study will be conducted in accordance with the ethical principles contained in the Helsinki Declaration. The final study protocol was approved by the Ethics Independent Committee of the Azienda Ospedaliero Universitaria di Cagliari (approval record N. PG/2015/16964).
Informed consent The interviewer will give clear and comprehensive information about the nature and the assumptions of the study to the respondents. Participants will also be informed of the possibility of interrupting the interview and withdrawing the consent to the study at any time. Interviewees will be required to sign an informed consent form.
Data protection The subjects enrolled in the study will be given information about data protection and the privacy law. The interviewer will explain that the study data will be placed in a database with anonymous codes to maintain confidentiality, in accordance with local data protection laws.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
This study's enrollment of 100 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Azienda Ospedaliero Universitaria di Cagliari is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Compared within Cognitive Dysfunction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mental Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Group 1: 50 subjects with chronic hepatitis HCV-related, which are eligible to be immediately treated with new antiviral drugs.
Group 2: 50 subjects with chronic hepatitis HCV-related, which are eligible to be treated with new antiviral drugs but are in wait list.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
Other: Neuropsychiatric screening
Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
Other: Neuropsychiatric screening
Psychiatric diagnosis through: 1. clinical interview 2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version); 3. HAM-D (Hamilton Scale for Depression); 4. PHQ-9 (Patient's Health Questionnaire-9 items); 5. MDQ (Mood Disorders Questionnaire); 6. YMRS (Young Mania Rating Scale); 7. ASRM (Altman Self Rating Mania scale); 8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry). Assessment of Quality of Life: 9. SF-12 (Short Form Health Survey-12 items). Neuropsychological screening: l) Addenbrooke's Cognitive Examination (ACE-R).
Short Form Health Survey-12 item (SF-12)
Self-report questionnaire that examines the following dimensions of well-being: vitality, physical function, physical pain, perception of general health, mental, physical, and emotional health, social role.
Time frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months
Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS)
semi- structured interview to diagnose most of the psychiatric disorders, consistent with the diagnostic criteria of the DSM IV (Diagnostic and Statistical Manual of Mental Disorders, 4th ed.)
Time frame: Baseline (T0)
Hamilton Scale for Depression (HAM-D)
clinical evaluation scale of the following depressive features: anxiety and somatization, suicidal thoughts, weight loss, cognitive disorders, activity problems, depressive retardation, sleep disturbances, and insight. It consists of 21 items, with scores from 0 to 3. Scoring 8-17 is indicative of mild depression; 18-24 moderate depression; a score\> 25 indicates a severe depression.
Time frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months
Patient's Health Questionnaire-9 items (PHQ-9)
Self-report questionnaire based on the DSM IV Major Depressive Disorder Diagnostic Criteria, investigating the presence and severity in the previous 2 weeks of 9 depressive symptoms, such as depressed mood, anhedonia, sleep and food disorders, fatigue, difficulty concentrating, motor behavior disorders, loss of self-esteem, suicidal ideation; the cut-off for minor depressive disorder is represented by scores ≥5, the one for major depressive disorder by scores ≥10. The questionnaire can be administrated by phone.
Time frame: Baseline (T0), and change from baseline: at two (T1) and four (T2) weeks, two (T3), three (T4), four (T5), five (T6), and six (T7) months.
Mood Disorders Questionnaire (MDQ)
Self-report 17-item questionnaire for lifetime screening of bipolar spectrum disorders (Type I and II Bipolar Disorder), through DSM IV diagnostic criteria; the cut-off is for scores ≥7
Time frame: Baseline (T0)
Young Mania Rating Scale (YMRS)
11-item questionnaire, evaluating the severity of manic/hypomanic symptoms (excitement, dysphoria, logorrhea, disorders of form and content of thought, sleep disturbances, aggression, appearance and clothing, insight). A score ≥12 suggests the presence of a manic/hypomanic episode
Time frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months
Altman Self Rating Mania Scale (ASRM)
self-administered 5-item scale that evaluates the presence and severity in the previous week of manic and hypomanic symptoms, such as manic/irritable mood, increased self-esteem, reduced need for sleep, loquacity, hyperactivity; a score ≥ 6 indicates a high likelihood of a manic or hypomanic episode. It can be administered by phone
Time frame: Baseline (T0), and change from baseline: at two (T1) and four (T2) weeks, two (T3), three (T4), four (T5), five (T6), and six (T7) months.
Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN)
21-item questionnaires that investigates the difficulties in sleep, daily activities, social relationships, and nutrition, and how these difficulties relate to biological rhythms
Time frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months
Addenbrooke's Cognitive Examination (ACE-R)
short cognitive test, which evaluates five cognitive domains: attention/orientation, memory, verbal fluency, language, visual-spatial abilities. The test, with a maximum score of 100 and a mild cognitive impairment cut-off of 66, includes the Mini Mental State Examination (MMSE).
Time frame: Baseline (T0), and change from baseline at three (T4) and six (T7) months
Plan to share: Undecided
Ran from Nov 2015 to primary completion in Jul 2018, 32 months.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's 32 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero Universitaria di Cagliari